BRISTOL MYERS SQUIBB

John joins Trialbee for its global team, industry-leading patient recruitment platform, and Swedish culture, aiming to contribute to equity in clinical research.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.

FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.

OBiS Insights pre-meeting ESMO24 report profiles 275 new, unapproved cancer drugs, classified as 40% antibody-based, 37% small molecule, and 23% mixed bag. The report excludes drugs not in abstract titles and will update during the conference. 43% of these drugs were discussed at recent ASCO24 meetings.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.

Illumina's TruSight Oncology Comprehensive, an FDA-approved IVD biomarker test kit, detects variants in 517 genes across nearly 30 solid tumor types, enabling personalized targeted therapies and faster treatment interventions within 4-5 days.

Bristol Myers Squibb's schizophrenia drug KarXT, with a PDUFA date of 26 September 2024, shows strong clinical data and a differentiated mechanism. Concerns over its twice-daily dosing led Terran Biosciences to develop a once-daily oral and multi-month injectable prodrug version, TerXT and TerXT LAI, aiming to improve adherence. KarXT's potential to avoid traditional antipsychotic side effects like weight gain and diabetes risks is highlighted, with GlobalData forecasting $2.99bn in sales by 2030.